Posted by Michael Wonder on 30 Dec 2020
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List
28 December 2020 - Zai Lab today announced that Zejula has been included in the updated National Reimbursement Drug List released by China’s National Healthcare Security Administration.
Zejula (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase inhibitor with national Category 1 designation.
It has been included in the National Reimbursement Drug List as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
